Published in Hepatitis Weekly, September 9th, 1996
H-BIG is an immunotherapeutic product for the prophylaxis of hepatitis B virus transmission. Under the program, the company has initiated a bioequivalence trial to compare its H-BIG formulation with the currently marketed formulation which has been distributed by NABI since 1992. Preliminary data from a recently-completed study showed sufficient comparability between the two formulations to support initiation of this pivotal bioequivalence trial.
"In line with our strategy of developing NABI's...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.